시장보고서
상품코드
1149499

세계의 알츠하이머병 진단 시장 예측 : 인사이트, 경쟁 상황, 시장(2027년)

Alzheimer´s Disease Diagnostic Market Insights, Competitive Landscape and, Market Forecast - 2027

발행일: | 리서치사: DelveInsight Business Research LLP | 페이지 정보: 영문 100 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 알츠하이머병 진단 시장 규모는 2022-2027년 예측 기간 동안 10.97%의 CAGR로 확대될 것으로 예측되고 있습니다. 시장은 전 세의에서 알츠하이머병 진단약 규제 인가가 증가하는 등의 요인에 의해 시장 성장이 전망되고 있습니다. 또한 사고와 노동재해 등으로 인한 두부 외상 증가와 노인 인구 증가로 알츠하이머병 유병률이 상승하여 전 세계적으로 알츠하이머병 진단 장치 수요가 증가하고 있습니다.

세계의 알츠하이머병 진단(Alzheimer's Disease Diagnostic) 시장을 조사했으며 시장 주요 요약와 더불어 진단 유형별, 최종 사용자별, 지역별 동향, 시장에 진입하는 기업 프로필 등을 제공합니다.

목차

제1장 알츠하이머병(AD) 진단 시장 리포트 소개

제2장 알츠하이머병(AD) 진단 시장 주요 요약

제3장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제4장 알츠하이머병(AD) 진단 시장 주요 요인 분석

  • 알츠하이머병(AD) 진단 시장 촉진 요인
  • 알츠하이머병(AD) 진단 시장 억제 요인과 과제
  • 알츠하이머병(AD) 진단 시장 기회

제5장 알츠하이머병(AD) 진단 시장에 관한 포터의 5가지 경쟁요인 분석

제6장 알츠하이머병(AD) 진단 시장 COVID-19의 영향 분석

제7장 알츠하이머병(AD) 진단 시장 레이아웃

  • 진단 유형별
  • 최종 사용자별
  • 지역별

제8장 알츠하이머병(AD) 진단 시장에서 기업과 제품 프로필

  • F. Hoffmann-La Roche Ltd.
  • General Electric Company
  • 23andMe, Inc.
  • Lilly
  • Fujirebio
  • Siemens Medical Solutions USA, Inc.
  • Diadem srl.
  • Todos Medical
  • DISCERN(TM)
  • FUJIFILM Holdings America Corporation
  • Koninklijke Philips NV
  • CANON MEDICAL SYSTEMS EUROPE BV
  • Shimzadu Corporation.
  • Laboratory Corporation of America(R) Holdings
  • Bruker
  • Magnetica.
  • IMRIS, Deerfield Imaging, Inc.
  • MR Solutions
  • Hyperfine, Inc.
  • Neusoft Corporation

제9장 KOL 견해

제10장 프로젝트 접근

제11장 DelveInsight 정보

제12장 면책사항과 문의

NJH 22.11.18

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET BY DIAGNOSTICS TYPE (BRAIN IMAGING [COMPUTED TOMOGRAPHY (CT), MAGNETIC RESONANCE IMAGING (MRI), POSITRON EMISSION TOMOGRAPHY (PET), AND OTHERS], GENETIC TESTING, BLOOD BASED TESTS, AND OTHERS), BY END-USER (HOSPITALS & CLINICS, DIAGNOSTIC CENTERS, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST TILL 2027 OWING TO THE INCREASING PREVALENCE AND INCIDENCE OF BRAIN INJURY, DIMENTIA, ALZHEIMER'S DISEASES, AND OTHERS, AND THE RISING BURDEN OF GERIATRIC POPULATION ACROSS THE GLOBE.

The global Alzheimer's disease (AD) diagnostic market will grow at a CAGR of 10.97% during the forecast period from 2022 to 2027. The Alzheimer's disease (AD) diagnostic market is observing an optimistic market growth due to the factors such as rise in the regulatory approvals for Alzheimer's disease (AD) diagnostics across the globe. Further, the rising prevalence of head injuries owing to the accidents, workplace injuries, and others, and the rise in geriatric population will increase the prevalence of Alzheimer disease, thereby increasing the demand of the Alzheimer disease diagnostic devices across the globe. Additionally, the increasing research and development of novel biomarkers, presence of key players in the market, increasing product launches and approvals, and other will create a requisite for Alzheimer disease diagnostics in the upcoming years. Therefore, the market for Alzheimer's disease (AD) diagnostic is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET DYNAMICS:

One of the key aspect for driving the Alzheimer's disease (AD) diagnostic market is the rising prevalence of dementia across the globe. Alzheimer's is a type of dementia that affects memory, thinking and behavior. Thus, the increasing prevalence of dementia will increase the prevalence of Alzheimer disease, ultimately increasing the demand of its diagnostic devices. For instance, as per the World Health Organization (WHO) 2022, it was concluded that, worldwide, around 55 million people have dementia, with over 60% living in low- and middle-income countries. Also, as the proportion of older people in the population is increasing in nearly every country, this number is expected to rise to 78 million in 2030 and 139 million in 2050.

Furthermore, the rising regulatory approval for Alzheimer's disease (AD) diagnostic is expected to be another key factor for driving the Alzheimer's disease (AD) diagnostic market. Various product launches in this arena is several markets is driving the market growth.

For instance, in May 2022, Fujirebio Diagnostics, a global leader in the field of high quality in vitro diagnostics (IVD), received a green light from the US Food and Drug Administration (FDA), for its Lumipulse G B-Amyloid Ratio (1-42/1-40) test, which is designed for people who have cognitive impairment and are 55 years of age or older. The test was also designated as a breakthrough device, allowing it to pass through a quicker review procedure for goods that fill an unmet need.

Additionally, in February 2022, Diadem, pure diagnostic company, received CE-IVD mark for its non-invasive plasma-based AlzoSure Predict prognostic blood test which is used to detect Alzheimer's disease (AD) in the early stages.

Hence, the rising regulatory approvals for Alzheimer's disease (AD) diagnostic showing the need for diagnosis test owing to the rising prevalence of disease, thereby driving the Alzheimer's Disease (AD) Diagnostic overall market during the forecast period from 2022-2027.

Therefore, the factors stated above collectively will drive the overall for Alzheimer's disease (AD) diagnostic market during the forecast period from 2022-2027.

However, high cost of brain imaging, stigma and lack of awareness about the diagnosis of Alzheimer disease, and others may prove to be challenging factors for Alzheimer's disease (AD) diagnostic market growth.

The Alzheimer's disease (AD) diagnostic market was negatively impacted during the period of COVID- 19 pandemic owing to the decreased number of diagnostics tests due to the huge spread of COVID-19 infection across the globe. Further, in order to curb the spread of infection the government across the globe imposed strict lockdown rules, resulting in the shortage of supply chains, raw materials, and other resources in the market, leading to the decreased manufacturing of all the medical devices. Moreover, the patients and physicians postponed many elective surgeries, diagnostic tests, laboratory visits, and other healthcare facilities in order to stop the spread of the infection, thereby decreasing the number of in-patient visits in hospitals and clinics for diagnosis and treatment. However, vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape, which has initiated the process of resumption of regular healthcare services such as regular out-patients visits for treatments and diagnosis in hospitals, clinics, and laboratories, thereby bringing the demand for products on track in the alzheimer's disease (AD) diagnostic devices market.

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET SEGMENT ANALYSIS:

Alzheimer's Disease (AD) Diagnostic Market by Diagnostics Type (Brain Imaging [Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Others], Genetic Testing, Blood Based Tests, and Others), End-User (Hospitals & Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the diagnostics type segment of the Alzheimer's disease (AD) diagnostic market, the computer tomography (CT) segment is expected to have a significant revenue share in the year 2021. This was primarily owing to the key benefits related to computer tomography (CT).

For instance, CT scans are used to detect the loss of brain mass linked to Alzheimer's Disease (AD) as well as they allows to take a detailed look inside the brain.

Further, it helps to collect multiple images of an area of the brain from different angles. Additionally, the scan helps to differentiate Alzheimer's disease (AD) from other types of dementia such as vascular dementia, mixed dementia, and others.

Moreover, increased launches of CT scans for brain imaging also increases the Alzheimer's disease (AD) diagnostics market demand. For instance, in May 2021, Koninklijke Philips N.V, a global leader in health technology, announced the launch of its pectral detector-based Spectral Computed Tomography (CT) 7500 system. The system delivers high quality spectral images for every patient including head scans and others.

Therefore, owing to the advantages and applications associated with CT segment along with the increasing product launches in the market, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global Alzheimer's disease (AD) diagnostic market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET:

Among all the regions, North America is expected to dominate the global medical device testing services in the year 2021 and is expected to do the same during the forecast period from 2022-2027. This can be ascribed to rising prevalence of head injuries, rise in geriatric population, rising product launches and approvals in the region, the presence of key market players in the region, and others will increase the demand of Alzheimer's disease (AD) diagnostic in the given forecast period.

For instance, according to the latest data available from the American Society for Biochemistry and Molecular Biology data published in the year 2021, in the United States, a brain injury occurs every nine seconds, resulting in more than 3.5 million incidents each year. Moreover, as per the above referenced source and statistics, about 2.8 million people suffers from traumatic brain injury (TBI) each year in the United States from which 2,80,000 resulting in hospitalizations. Therefore, rising cases for head injuries such as Traumatic Brain Injury (TBI) includes the high risk for developing the Alzheimer's disease.

Also, the increasing prevalence of Alzheimer disease in the United States will drive the market of the diagnostic devices. As per the data provided by the Alzheimer Association (2022), more than 6 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. The increasing prevalence of Alzheimer disease in the United States will increase the demand of its diagnostics devices, ultimately leading to the increased overall market growth.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the Alzheimer's disease (AD) diagnostic market.

ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET KEY PLAYERS:

Some of the key market players operating in the Alzheimer's Disease (AD) Diagnostic market includes F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET:

  • In May 2022, the U.S. Food and Drug Administration today permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer's disease.
  • In May 2020, Lilly, a global health care leader, received US Food and Drug Administration (FDA) approval for its TAUVID™, a radioactive diagnostic agent for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being assessed for Alzheimer's disease (AD).

KEY TAKEAWAYS FROM THE ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET REPORT STUDY

  • Market size analysis for current Alzheimer's Disease (AD) Diagnostic market size (2020), and market forecast for 5 years (2021-2027)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Alzheimer's disease (AD) Diagnostic market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global Alzheimer's disease (AD) Diagnostic market.
  • Various opportunities available for the other competitor in the Alzheimer's disease (AD) Diagnostic market space.
  • What are the top performing segments in 2020? How these segments will perform in 2027.
  • Which is the top-performing regions and countries in the current Alzheimer's disease (AD) Diagnostic market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Alzheimer's disease (AD) Diagnostic market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET REPORT STUDY

  • Alzheimer's Disease (AD) Diagnostic products providers
  • Research organizations and consulting companies
  • Alzheimer's Disease (AD) Diagnostic -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Alzheimer's Disease (AD) Diagnostic
  • Various end users who want to know more about the Alzheimer's disease (AD) Diagnostic market and latest technological developments in the Alzheimer's disease (AD) Diagnostic market.

FREQUENTLY ASKED QUESTIONS FOR ALZHEIMER'S DISEASE (AD) DIAGNOSTIC MARKET:

1. What is Alzheimer's Disease (AD) Diagnostic?

The Alzheimer's disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. The devices and tests used to assess memory impairment, thinking skills, functional abilities, behavior changes, and others in order to diagnose the Alzheimer's disease, are known as Alzheimer's disease diagnostic devices.

2. What is the global market for Alzheimer's disease (AD) Diagnostic?

The global Alzheimer's disease (AD) diagnostic market will grow at a CAGR of 10.97% during the forecast period from 2022 to 2027.

3. What are the drivers for global Alzheimer's disease (AD) Diagnostic market?

The Alzheimer's disease (AD) diagnostic market is witnessing a positive market growth owing to the factors such as the rise in the regulatory approvals for Alzheimer's disease (AD) diagnostics, rising prevalence of head injuries, rise in geriatric population, increasing research and development of novel biomarkers, and others will create an exigency for the Alzheimer's disease (AD) Diagnostic market.

4. Who are the key players operating in the global Alzheimer's disease (AD) diagnostic market?

Some of the key market players operating in the Alzheimer's disease (AD) Diagnostic market includes F. Hoffmann-La Roche Ltd., General Electric Company, 23andMe, Inc., Lilly, Fujirebio, Siemens Medical Solutions USA, Inc., Diadem srl., Todos Medical, DISCERN™, FUJIFILM Holdings America Corporation, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS EUROPE B.V., Shimzadu Corporation., Laboratory Corporation of America® Holdings, Bruker, Magnetica., IMRIS, Deerfield Imaging, Inc., MR Solutions, Hyperfine, Inc., Neusoft Corporation, and others.

5. Which region has the highest share in Alzheimer's disease (AD) Diagnostic market?

Among all the regions, North America is estimated to amass the significant revenue share in the global Alzheimer's disease (AD) Diagnostic market. This can be ascribed to the rising prevalence of head injuries, rise in geriatric population, and the presence of key market players in the region are factors which acts as a supportive factor for the North America Alzheimer's disease (AD) diagnostic market growth.

Table of Contents

1. Alzheimer's Disease (AD) Diagnostic Market Report Introduction

2. Alzheimer's Disease (AD) Diagnostic Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment

3. Regulatory Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Alzheimer's Disease (AD) Diagnostic Market Key Factors Analysis

  • 4.1 Alzheimer's Disease (AD) Diagnostic Market Drivers
    • 4.1.1 Rise in the Regulatory Approvals for Alzheimer's Disease (AD) Diagnostics
    • 4.1.2 Rising Prevalence of Head Injuries
    • 4.1.3 Rise in Geriatric Population
    • 4.1.4 Increasing Research and Development of Novel Biomarkers
  • 4.2 Alzheimer's Disease (AD) Diagnostic Market Restraints and Challenges
    • 4.2.1 High Cost of Brain Imaging
    • 4.2.2 Due to Stigma and Lack of Awareness
  • 4.3 Alzheimer's Disease (AD) Diagnostic Market Opportunities
    • 4.3.1 Increasing Research and Development
    • 4.3.2 Availability of Large Pipeline Diagnostics Products
    • 4.3.3 Development of Non-Invasive Techniques

5. Alzheimer's Disease (AD) Diagnostic Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Alzheimer's Disease (AD) Diagnostic Market

7. Alzheimer's Disease (AD) Diagnostic Market Layout

  • 7.1 By Diagnostics Type
    • 7.1.1 Brain Imaging
      • 7.1.1.1 Computed tomography (CT)
      • 7.1.1.2 Magnetic resonance imaging (MRI)
      • 7.1.1.3 Positron emission tomography (PET)
      • 7.1.1.4 Others
    • 7.1.2 Genetic testing
    • 7.1.3 Blood based tests
    • 7.1.4 Others
  • 7.2 By End-User
    • 7.2.1 Hospitals & Clinics
    • 7.2.2 Diagnostic Centers
    • 7.2.3 Others
  • 7.3 By Geography
  • 7.3.1 North America
      • 7.3.1.1 United States Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.1.2 Canada Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.1.3 Mexico Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
    • 7.3.2 Europe
      • 7.3.2.1 France Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.2.2 Germany Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.2.3 United Kingdom Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.2.4 Italy Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.2.5 Spain Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.2.6 Rest of Europe Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.3.2 Japan Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.3.3 India Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.3.4 Australia Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.3.5 South Korea Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.3.6 Russia Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.3.7 Rest of Asia Pacific Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
    • 7.3.4 Rest of the World (RoW)
      • 7.3.4.1. Middle East Alzheimer's Disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.4.2 Africa Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)
      • 7.3.4.3 South America Alzheimer's disease (AD) Diagnostic Market in USD million (2019-2027)

8. Alzheimer's Disease (AD) Diagnostic Market Company and Product Profiles

  • 8.1 F. Hoffmann-La Roche Ltd.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 General Electric Company
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 23andMe, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Lilly
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 Fujirebio
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5. Entropy
  • 8.6 Siemens Medical Solutions USA, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy
  • 8.7 Diadem srl.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5. Entropy
  • 8.8 Todos Medical
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5. Entropy
  • 8.9 DISCERN™
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5. Entropy
  • 8.10 FUJIFILM Holdings America Corporation
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5. Entropy
  • 8.11 Koninklijke Philips N.V.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5. Entropy
  • 8.12 CANON MEDICAL SYSTEMS EUROPE B.V.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5. Entropy
  • 8.13 Shimzadu Corporation.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5. Entropy
  • 8.14 Laboratory Corporation of America® Holdings
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5. Entropy
  • 8.15 Bruker
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5. Entropy
  • 8.16 Magnetica.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5. Entropy
  • 8.17 IMRIS, Deerfield Imaging, Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5. Entropy
  • 8.18 MR Solutions
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5. Entropy
  • 8.19 Hyperfine, Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5. Entropy
  • 8.20 Neusoft Corporation
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제